Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma

Jennifer Ann Wargo, Rodabe Navroze Amaria, Merrick I. Ross, Robyn P. M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna Pradyuman Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A. Scolyer, Helen Rizos, John F. Thompson, Kerwin Shannon, Andrew Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)TPS9091-TPS9091
Number of pages1
JournalJournal of Clinical Oncology
Volume33
Issue number15 supplement
DOIs
Publication statusPublished - 20 May 2015
EventAnnual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States
Duration: 31 May 20134 Jun 2013

Cite this

Wargo, J. A., Amaria, R. N., Ross, M. I., Saw, R. P. M., Gershenwald, J. E., Hwu, P., ... Long, G. V. (2015). Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. Journal of Clinical Oncology, 33(15 supplement), TPS9091-TPS9091. https://doi.org/10.1200/jco.2015.33.15_suppl.tps9091